Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.35 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097207 | 0.84 | AR (0.44) | ARKDM4ESMN1; SMN2PRKCBPRKCA | |
| SCHEMBL6097786 | 0.83 | DYRK1A (0.43) | ARNR3C1PGRNR3C2AURKA | |
| SCHEMBL6096554 | 0.81 | DYRK1A (0.41) | ARNR3C1PGRNR3C2AURKA | |
| SCHEMBL6096052 | 0.81 | GPR84 (0.40) | ARNR3C1PGRNR3C2AURKA | |
| SCHEMBL6095726 | 0.81 | ALDH1A1 (0.44) | ARNR3C1PGRNR3C2KDM4E | |
| SCHEMBL6094634 | 0.79 | PARP1 (0.40) | ARNR3C1PGRNR3C2KDM4E | |
| SCHEMBL6097186 | 0.79 | MEN1 (0.37) | ARNR3C1PGRNR3C2 | |
| SCHEMBL6095205 | 0.79 | CSNK2A2 (0.41) | ARKIF11KDM4ESMN1; SMN2PRKCB | |
| SCHEMBL6099160 | 0.76 | CSNK2A2 (0.34) | — | |
| SCHEMBL6094232 | 0.76 | AR (0.34) | ARKDM4ESMN1; SMN2PRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057052-B2 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2004050014-A2 | SETEROCYCLIC QUINONES AS PHARMACEUTICAL AGENTS | DUKE UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | NQO1, RECQL, SDHA | AR 4343/4885NR3C1 3050/4885PGR 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.